NCT01552967Unknown2 期
A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2012年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Overall response rate according to RECIST 1.1
研究概览
简要总结
This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and capecitabine on metastatic colorectal adenocarcinoma in the first-line therapy.
详细描述
Primary endpoint: Overall Response Rate
Secondary endpoint: Time to progression, overall survival, safety data
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent;
- •Patients with histologically or cytologically confirmed stage IV colorectal adenocarcinoma whose ECOG performance status are 0-2;
- •Presence of measurable disease by radiographic study (including CT or MRI scan, or chest x-ray) or physical examination;
- •At least 3 weeks since last major surgery;
- •At least 12 months since last adjuvant chemotherapy;
- •At least 6 weeks since prior radiotherapy providing that the extent and site of radiotherapy fields are such that marked bone marrow suppression is NOT expected;
- •Patients who have received palliative radiotherapy must have recovered from any reversible toxic effects e.g. nausea and vomiting caused by radiation of fields;
- •Patients with reproductive potential must use effective BC;
- •Required Screening Laboratory Criteria:
- •Hemoglobin 90g/L
- •WBC 3.5 x 109/L
- •Neutrophils 1.5 x 109/L
- •Platelets 100 x 109/L
- •Creatinine 133 umol/L and creatinine clearance 60 mL/min
- •A probable life expectancy of at least 6 months;
排除标准
- •Brain metastases;
- •Female of childbearing potential, pregnancy test is positive;
- •Concomitant malignancies or previous malignancies other than colorectal cancer within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or low grade prostate cancer;
- •Active infection;
- •Concurrent severe medical problems unrelated to the malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk;
- •Sexually active patients refusing to practice adequate contraception;
- •Patients with conditions which might affect absorption of an oral drug (for example intermittent obstruction) unless discussed and agreed with principal investigator;
- •History of grade 3 or 4 toxicity to fluoropyrimidines;
- •Pre-existing neuropathy ≥ NCI CTC grade 2.
结局指标
主要结局
Overall response rate according to RECIST 1.1
时间窗: One year
次要结局
- Time to progression(One year)
- overall survival(One Year)
- Safety data of this regimen(One Year)
研究者
Jian Xiao
Principal Investigator
Sixth Affiliated Hospital, Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric AdenocarcinomaGastric AdenocarcinomaNCT01552980Sixth Affiliated Hospital, Sun Yat-sen University30
尚未招募
2 期
A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian CancerOvarian CancerNCT06211023Suzhou Suncadia Biopharmaceuticals Co., Ltd.520
已完成
2 期
A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury SubjectsBurn InjuryNCT02619851Anterogen Co., Ltd.20
已完成
2 期
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDGPmm2-CDGPhosphomannomutase 2 DeficiencyNCT05549219Glycomine, Inc.27
已完成
2 期
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia (B-CLL)NCT00328198Genzyme, a Sanofi Company86